Burden of Anemia among Human Immunodeficiency Virus-Positive Adults on Highly Active Antiretroviral Therapy at Hawassa University Compressive Specialized Hospital, Hawassa, Ethiopia

Table 2

Baseline clinical characteristics of adult HIV patients on HAART at Hawassa university specialized hospital, 2021 (n = 244).

Background characteristics	Not anemic N (%)	Anemic N (%)	COR (95% CI)
TB
No	165 (67.6%)	57 (23.3%)	Ref
Yes	6 (2.5%)	16 (6.6%)	7.719 (2.882–20.679)
BMI
>18.5	144 (59%)	39 (16%)	Ref
≤18.5	27 (11.1%)	34 (13.9%)	4.650 (2.509–8.616)
ART regimen
Non-AZT-containing	168 (68.9%)	62 (25.4%)	9.935 (2.682–36.801)
AZT-containing	3 (1.2%)	11 (4.5%)	Ref
Duration of ART
6 months–1 year	31 (12.7%)	17 (7%)	Ref
1–5 years	74 (30.3%)	26 (10.7%)	0.641 (0.305–1.345)
6–10 years	37 (15.2%)	18 (7.4%)	0.887 (0.392–2.008)
>10 years	29 (11.9%)	12 (4.9%)	0.755 (0.308–1.848)
Duration of HIV
6 months–1 year	29 (11.9%)	17 (7%)	Ref
1–5 years	75 (30.7%)	25 (10.2%)	0.569 (0.268–1.204)
6–10 years	38 (15.6%)	19 (7.8%)	0.853 (0.378–1.924)
>10 years	29 (11.9%)	12 (4.9%)	0.706 (0.287–1.737)
WHO stage
Stage I &II	154 (63.1%)	56 (23%)	Ref
Stage III & IV	17 (7%)	17 (7%)	2.750 (1.314–5.756)
Cotrimoxazole
No	147 (60.2%)	43 (17.6%)	Ref
Yes	24 (9.8%)	30 (12.3%)	4.273 (2.264–8.066)
CD4 counts
≥500	97 (39.8%)	23 (9.4%)	Ref
200–500	55 (22.5%)	27 (11.1%)	2.070 (1.084–3.954)
<200	19 (7.8%)	23 (9.4%)	5.105 (2.390–10.904)
Mean cell volume
<70	10 (4.1%)	6 (2.5%)	Ref
70–100	84 (34.4%)	34 (13.9%)	0.675 (0.227–2.002)
>100	77 (31.6%)	33 (13.5%)	0.714 (0.240–2.127)